title: Pepsinogen II can be a potential surrogate marker of morphological changes in corpus before and after H. pylori eradication.
abstract: BACKGROUND
  The aim of this investigation is to study the relationship between gastric morphology and serum biomarkers before and after Helicobacter pylori eradication.
  
  
  METHODS
  First-degree relatives of gastric cancer patients underwent gastroscopy before and 2.5 years after H. pylori eradication. The morphological changes in two categories (normal to mild and moderate to severe) were compared with level of pepsinogens I and II before eradication (n = 369), after eradication (n = 115), and in those with persistent infection (n = 250).
  
  
  RESULTS
  After eradication, pepsinogen I decreased to 70% and pepsinogen II to 45% of the previous values. Unlike pepsinogen II and pepsinogen I to II ratio that were affected by the severity of inflammation and atrophy in corpus in all groups, pepsinogen I generally did not change. After eradication, subjects with high mononuclear infiltration in corpus had lower pepsinogen I (54 versus 77.1 μ/mL), higher pepsinogen II (9.4 versus 6.9 μ/mL), and lower ratio (7.9 versus 11.6) than those without (P < 0.05).
  
  
  CONCLUSIONS
  Pepsinogen II is a good marker of corpus morphological changes before and after H. pylori eradication.
authors.affiliation: Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 1411713135, Iran.
authors.forename: Sadegh
authors.initials: S
authors.lastname: Massarrat
authors.affiliation: Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 1411713135, Iran.
authors.forename: Arghavan
authors.initials: A
authors.lastname: Haj-Sheykholeslami
authors.affiliation: Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 1411713135, Iran.
authors.forename: Ashraf
authors.initials: A
authors.lastname: Mohamadkhani
authors.affiliation: Research Center for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985711151, Iran.
authors.forename: Nasrin
authors.initials: N
authors.lastname: Zendehdel
authors.affiliation: Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 1411713135, Iran.
authors.forename: Ali
authors.initials: A
authors.lastname: Aliasgari
authors.affiliation: Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 1411713135, Iran ; Gastrointestinal and Liver Diseases Research Center, Firoozgar Hospital, Iran University of Medical Sciences, Tehran 1593748711, Iran.
authors.forename: Naser
authors.initials: N
authors.lastname: Rakhshani
authors.affiliation: Institute of Pathology, Klinikum Kulmbach, 95326 Kulmbach, Germany.
authors.forename: Manfred
authors.initials: M
authors.lastname: Stolte
authors.affiliation: Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran 1411713135, Iran.
authors.forename: Seyed Mehdi
authors.initials: SM
authors.lastname: Shahidi
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D016481:Helicobacter Infections / Q000097:blood* / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D020115:Pepsinogen C / Q000097:blood*; D013274:Stomach Neoplasms / Q000097:blood* / Q000601:surgery
chemical_list: D014408:Biomarkers, Tumor; D020115:Pepsinogen C